Retinal Biologics Market Research Report Information By Drug Class (TNF-a Inhibitor and VEGF-A Antagonist), By Indication (Macular Degeneration, Diabetic Retinopathy, Uveitis, and Others), By Distribution Channel (Hospitals and Clinics, Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2032.

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Retinal Biologics Market, by Drug Class

1.1.2. Global Retinal Biologics Market, by Indication

1.1.3. Global Retinal Biologics Market, by Distribution Channel

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Breakdown of Primary Respondents

3.5. Forecasting Indications

3.6. Research Methodology for Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.2.1. R&D and Designing

5.2.2. Manufacturing

5.2.3. Distribution & Sales

5.2.4. Post Sales Services

5.3. Impact of COVID 19 on Retinal Biologics Market

5.3.1. Impact on Market Value in 2023 and 2021

5.3.2. Clinical Trial Impact

5.3.3. Impact of Demand

5.3.4. Strategies to Overcome the Challenges

6. GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS

6.1. Overview

6.2. TNF-α Inhibitor

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

6.3. VEGF-A Antagonist

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

7. GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION

7.1. Overview

7.2. Macular Degeneration

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

7.3. Diabetic Retinopathy

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

7.4. Uveitis

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

7.5. Others

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

8. GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

8.3. Pharmacies

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

8.4. Others

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

9. GLOBAL RETINAL BIOLOGICS MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitor Dashboard

10.3. Major Growth Strategy in the Global Retinal Biologics Market

10.4. Competitive Benchmarking

10.5. The Leading Player in terms of Number of Developments in the Global Retinal Biologics Market

10.6. Key Developments & Growth Strategies

10.6.1. New Product Launch/Service Deployment

10.6.2. Merger & Acquisition

10.6.3. Joint Ventures

10.7. Major Players Financial Matrix & Market Ratio

10.7.1. Sales & Operating Income 2019

10.7.2. Major Players R&D Expenditure 2019

11. COMPANY PROFILES

11.1. Amgen, Inc.

11.1.1. Company Overview

11.1.2. Products/Services Offered

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. AbbVie Inc.

11.3. MeiraGTx Limited

11.4. Regeneron Pharmaceuticals Inc

11.5. Ocular Therapeutixc.

11.6. Spark Therapeutics

11.7. F. Hoffmann-La Roche Ltd.

11.8. Genentech

11.9. Johnson & Johnson

11.10. Others

12. APPENDIX

12.1. References

12.2. Related Reports

NOTE:

This table of content is tentative and subject to change as the research progresses.

  In section 11, only the top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.

  Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.

LIST OF TABLES

TABLE 1 GLOBAL RETINAL BIOLOGICS MARKET SYNOPSIS, 2017–2030

TABLE 2 GLOBAL RETINAL BIOLOGICS MARKET ESTIMATES & FORECAST, 2023–2030 (USD MILLION)

TABLE 3 GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 4 GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 5 GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 6 GLOBAL RETINAL BIOLOGICS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 7 NORTH AMERICA: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 8 NORTH AMERICA: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 9 NORTH AMERICA: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 10 US: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 11 US: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 12 US: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 13 CANADA: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 14 CANADA: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 15 CANADA: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 16 LATIN AMERICA: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 17 LATIN AMERICA: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 18 LATIN AMERICA: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 19 EUROPE: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 20 EUROPE: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 21 EUROPE: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 22 WESTERN EUROPE: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 23 WESTERN EUROPE: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 24 WESTERN EUROPE: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 25 EASTERN EUROPE: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 26 EASTERN EUROPE: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 27 EASTERN EUROPE: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 28 ASIA-PACIFIC: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 29 ASIA-PACIFIC: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 30 ASIA-PACIFIC: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: RETINAL BIOLOGICS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNELS, 2023–2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL RETINAL BIOLOGICS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL RETINAL BIOLOGICS MARKET

FIGURE 4 GLOBAL RETINAL BIOLOGICS MARKET SHARE, BY DRUG CLASS, 2019 (%)

FIGURE 5 GLOBAL RETINAL BIOLOGICS MARKET SHARE, BY INDICATION, 2019 (%)

FIGURE 6 GLOBAL RETINAL BIOLOGICS MARKET SHARE, BY DISTRIBUTION CHANNELS, 2019 (%)

FIGURE 7 GLOBAL RETINAL BIOLOGICS MARKET SHARE, BY REGION, 2019 (%)

FIGURE 8 AMERICAS: RETINAL BIOLOGICS MARKET SHARE BY REGION, 2019 (%)

FIGURE 9 NORTH AMERICA: RETINAL BIOLOGICS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 10 EUROPE: RETINAL BIOLOGICS MARKET SHARE, BY REGION, 2019 (%)

FIGURE 11 WESTERN EUROPE: RETINAL BIOLOGICS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 12 ASIA-PACIFIC: RETINAL BIOLOGICS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 13 MIDDLE EAST & AFRICA: RETINAL BIOLOGICS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 14 GLOBAL RETINAL BIOLOGICS MARKET: COMPANY SHARE ANALYSIS, 2019 (%)

FIGURE 15 AMGEN, INC.: KEY FINANCIALS

FIGURE 16 AMGEN, INC.: SEGMENTAL REVENUE

FIGURE 17 AMGEN, INC.: REGIONAL REVENUE

FIGURE 18 ABBVIE INC.: KEY FINANCIALS

FIGURE 19 ABBVIE INC..: SEGMENTAL REVENUE

FIGURE 20 ABBVIE INC.: REGIONAL REVENUE

FIGURE 21 MEIRAGTX LIMITED: KEY FINANCIALS

FIGURE 22 MEIRAGTX LIMITED: SEGMENTAL REVENUE

FIGURE 23 MEIRAGTX LIMITED: REGIONAL REVENUE

FIGURE 24 REGENERON PHARMACEUTICALS INC: KEY FINANCIALS

FIGURE 25 REGENERON PHARMACEUTICALS INC: SEGMENTAL REVENUE

FIGURE 26 REGENERON PHARMACEUTICALS INC: REGIONAL REVENUE

FIGURE 27 OCULAR THERAPEUTIXC.: KEY FINANCIALS

FIGURE 28 OCULAR THERAPEUTIXC.: SEGMENTAL REVENUE

FIGURE 29 OCULAR THERAPEUTIXC.: REGIONAL REVENUE

FIGURE 30 SPARK THERAPEUTICS: KEY FINANCIALS

FIGURE 31 SPARK THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 32 SPARK THERAPEUTICS: REGIONAL REVENUE

FIGURE 33 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS

FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: SEGMENTAL REVENUE

FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: REGIONAL REVENUE

FIGURE 36 GENENTECH: KEY FINANCIALS

FIGURE 37 GENENTECH: SEGMENTAL REVENUE

FIGURE 38 GENENTECH: REGIONAL REVENUE

FIGURE 39 JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 40 JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 41 JOHNSON & JOHNSON: REGIONAL REVENUE